小児性エアロファギーの治療におけるビフィドバクテリアと組み合わせたシメチコンの臨床効果
Ping He1, Fangqi Hu1, Le Wang1
1Department of Pediatrics, Anqing Municipal Hospital, Anqing, Anhui, China.
Frontiers in pediatrics
|September 2, 2025
まとめ
シメチコンはビフィドバクテリアと併用して,エアロファギーの小児における臨床効果と胃の排泄を有意に改善し,安全性を示した. この組み合わせ治療は 小児性エアロファギーの有望な治療法です
科学分野:
- 小児胃腸内科
- 薬理学について
- 微生物学
背景:
- 小児性エアロファギアには 複雑な原因と 多様でしばしば再発する 治療課題があります
- シメチコネオイルは,エアロファギアに対する安全で新しい治療薬として認識されています.
研究 の 目的:
- 小児性エアロファギーの治療におけるシメチコンとビフィドバクテリアの臨床的有効性と安全性を評価する.
- ビフィドバクテリア単独治療と組み合わせ治療を比較する.
主な方法:
- エロファギアと診断された 80人の子どもを対象とした研究です
- 治療群 (ビフィドバクテリア + シメチコン) と対照群 (ビフィドバクテリア単独治療) の比較
- 臨床的有効性,胃腸症状スコア (GSRS),胃運動性,および有害事象の評価
主要な成果:
- 併用療法群は,対照群と比較して,著しく高い臨床有効率 (92. 5% 対 75%) と低いGSRSスコアを示した.
- 治療群では胃の排泄率の有意な改善が観察されました.
- グループ間の有害事象の発生率は同等であった (7. 5% vs 15%),同様の安全性プロファイルを示した.
結論:
- シメチコンとビフィドバクテリウムを併用した治療は,小児性エアロファギーの症状を効果的に軽減し,胃の排泄を促進します.
- この組み合わせのアプローチは,小児性エアロファギア管理における臨床使用を支持する,良好な安全性と耐受性を示しています.
関連する概念動画
Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326
Esophageal Strictures-II: Clinical Features and Management
156
Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
156
Gastroesophageal Reflux Disease II: Clinical Features and Management
156
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
156
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
684
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
684


